WILMINGTON, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that Greg Mayes, Chief Executive Officer, will participate in the following investor conferences. Please contact your representative to…

Source

Previous articleThe Premiere of our New Short Film Vital Psychedelic Training: Creating Worldwide Community
Next articlePT448 – Ibogaine, Noribogaine, and the Challenges of Federal Drug Policy